
Zydus Cadila has received final approval from the US Food and Drug Administration (USFDA) to market Ibrutinib Capsules in the strengths of 70 mg and 140 mg, Cadila Healthcare said in a regulatory filing.
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/3t5dKfe
via
IFTTT
0 comments:
Post a Comment